📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 20:53
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Modi Naturals Bags ₹140 Cr Additional Ethanol Order; ESY 2025-26 Book Reaches ~₹540 Cr
Modi Naturals' wholly owned subsidiary, Modi Biotech Private Limited (MBPL), has secured an additional allocation of 1.98 crore litres of ethanol with an estimated value of ₹140 crore for ESY 2025-26 from Oil Marketing Companies (OMCs). Supplies under this allocation are scheduled to run until October 2026. This award is incremental to the existing order of approximately ₹400 crore (~47.9k KL), taking the cumulative ESY 2025-26 order book to ~₹540 crore. The ₹140 crore incremental win constitutes ~42.4% of the company's TTM revenue of ₹330 crore, offering strong top-line visibility.
Confidence: HIGH
What changedWholly owned subsidiary Modi Biotech secured an additional 1.98 crore litres (₹140 crore) ethanol supply allocation from OMCs for ESY 2025-26.
Why it mattersThe win expands the ESY 2025-26 order book to ~₹540 crore, substantially exceeding the company's TTM revenue of ₹330 crore and bolstering distillery segment revenue visibility.
Additional order value: ₹ 140 croresAdditional volume: 1.98 crore litresExisting order value: around ₹400 croreExisting order volume: ~47.9k KLSupply deadline: October 2026Additional order vs TTM revenue: ~42.4%
📅 Short termPositive sentiment driver as the sizable allocation confirms OMC demand and utilization ramp-up for the distillery segment through October 2026.
📈 Long termValidates the company's strategic transition toward grain-based ethanol manufacturing, establishing scale and operational track record with state-run OMCs under the national blending programme.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Raw material price volatility (grain feedstock) impacting distillery gross margins
- Customer concentration risk with government-backed OMC offtake agreements
- Execution and delivery adherence risks within the October 2026 timeframe
Key Highlights
Received an additional allocation of 1.98 crore litres of ethanol for ESY 2025-26 via subsidiary Modi Biotech.
Estimated value of the new order is ₹140 crore, equivalent to ~42.4% of TTM revenue (₹330 crore).
Supply period for the additional volume runs until October 2026.
Builds on an existing order of around ₹400 crore (~47.9k KL), lifting total ESY 2025-26 allocation to ~₹540 crore.
👀 What to Watch
Track quarterly ethanol execution volumes and operating margins in upcoming quarterly results, alongside progress on feedstock procurement and capacity utilization through October 2026.
Modi Naturals Q1 FY27 PAT up 19% to ₹12.5 Cr; Secures ₹140 Cr Additional Ethanol Order
Modi Naturals reported a 25.6% YoY rise in consolidated EBITDA to ₹22.2 Cr and a 19.1% YoY increase in PAT to ₹12.5 Cr for Q1 FY27, despite flat revenue at ₹155.6 Cr. Profitability was driven by the Ethanol division, where EBITDA margins expanded 510 bps YoY to 22.2% even with a 20-day maintenance shutdown. The company secured an additional ₹140 Cr order from OMCs for the balance Ethanol Supply Year (ESY) through October 2026, representing ~42.4% of TTM revenue (₹330 Cr). The expanded ethanol capacity of 282 KLPD (up from 130 KLPD in FY24) is scheduled to be fully operational by the end of August 2026.
Confidence: HIGH
What changedModi Naturals published its August 2026 investor presentation detailing Q1 FY27 results, a fresh ₹140 Cr OMC ethanol order, and the operationalization timeline for its 282 KLPD ethanol capacity expansion.
Why it mattersHigher ethanol capacity coupled with strong margins (22.2%) provides strong revenue visibility and operating leverage heading into H2 FY27.
Q1 FY27 Revenue: ₹155.6 CrQ1 FY27 EBITDA: ₹22.2 CrQ1 FY27 PAT: ₹12.5 CrAdditional Ethanol Order: ₹140 CrNew Order vs TTM Revenue: ~42.4%Total Ethanol Capacity: 282 KLPD
📅 Short termSuccessful ramp-up of the expanded ethanol unit by end of August 2026 will support higher production and revenue recognition over Q2 and Q3 FY27.
📈 Long termDoubling ethanol capacity alongside FMCG brand expansion in quick commerce supports sustained top-line scaling and structural margin improvement.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Ethanol raw material pricing fluctuations (e.g., FCI rice) and regulatory dependency on government offtake pricing.
- Thin margins in consumer edible oil bulk business amid commodity price volatility.
Key Highlights
Q1 FY27 consolidated PAT grew 19.1% YoY to ₹12.5 Cr on EBITDA of ₹22.2 Cr (+25.6% YoY) with revenue at ₹155.6 Cr (+0.4% YoY).
Ethanol division EBITDA expanded 22% YoY to ₹16.6 Cr with margins improving to 22.2% from 17.1% in Q1 FY26.
Bagged fresh ethanol supply orders worth ~₹140 Cr for the balance ESY period through October 2026.
Ethanol production capacity scaled to 282 KLPD (+117% over FY24) and is set to be fully operational by August 2026 end.
👀 What to Watch
Monitor the commercial ramp-up of the expanded 282 KLPD ethanol facility post-August 2026 and track delivery timelines of the ₹140 Cr OMC order book.
Q1 Net Profit Up 19.1% YoY to ₹12.50 Cr; Revenue Flat at ₹155.61 Cr
Modi Naturals reported a 19.1% YoY increase in consolidated Net Profit to ₹12.50 Cr for Q1 FY27 (quarter ended June 30, 2026), compared to ₹10.49 Cr in Q1 FY26. Consolidated Revenue from Operations remained virtually flat at ₹155.61 Cr versus ₹155.03 Cr in the year-ago period. Standalone edible oil business contributed ₹80.80 Cr in revenue and ₹2.88 Cr in PAT, with wholly owned subsidiary Modi Biotech Private Limited driving the remainder of consolidated performance. Diluted EPS rose to ₹9.44 from ₹7.87 in Q1 FY26.
Confidence: HIGH
What changedThe company reported its unaudited standalone and consolidated Q1 FY27 financial results showing steady revenue and margin-driven profit expansion.
Why it mattersDemonstrates sustained operational profitability from the consolidated entity (including the ethanol division) despite flat top-line growth in core agricultural/bulk segments.
Consolidated Revenue (Q1): ₹155.61 crConsolidated PAT (Q1): ₹12.50 crConsolidated PBT (Q1): ₹15.95 crDiluted EPS: ₹9.44Standalone Revenue (Q1): ₹80.80 cr
📅 Short termPositive for the stock due to robust bottom-line growth YoY, though sequential revenue moderated from Q4 levels.
📈 Long termLong-term trajectory depends on execution of the ethanol expansion strategy and scaling higher-margin branded consumer products.
⚠ Risk flags
- Seasonal volatility in raw material supplies for the bulk oil business
- Dependence on government-mandated ethanol blending policies and offtake pricing
Key Highlights
Consolidated PAT increased 19.1% YoY to ₹12.50 Cr (₹1,250.12 lakhs) from ₹10.49 Cr in Q1 FY26
Consolidated Revenue from Operations stood at ₹155.61 Cr vs ₹155.03 Cr in Q1 FY26
Profit Before Tax (PBT) expanded 18.7% YoY to ₹15.95 Cr vs ₹13.44 Cr
Diluted EPS improved to ₹9.44 per share compared to ₹7.87 in Q1 FY26
👀 What to Watch
Track capacity utilization and policy developments in the ethanol subsidiary (Modi Biotech), alongside branded consumer volume growth in upcoming quarterly results.
Modi Naturals Q1 Cons. PAT Rises 19.1% YoY to ₹12.50 Cr; Revenue Flat at ₹155.61 Cr
Modi Naturals reported consolidated revenue from operations of ₹155.61 Cr for the quarter ended June 30, 2026, up marginally by 0.37% YoY from ₹155.03 Cr. Consolidated Profit After Tax (PAT) grew 19.14% YoY to ₹12.50 Cr compared to ₹10.49 Cr in Q1 FY26, supported by operational efficiency. Diluted EPS expanded to ₹9.44 from ₹7.87 in the corresponding quarter of the previous year. On a standalone basis, revenue stood at ₹80.80 Cr with a PAT of ₹2.88 Cr.
Confidence: HIGH
What changedModi Naturals announced its Q1 financial results for the quarter ended June 30, 2026, delivering double-digit bottom-line growth.
Why it mattersShows healthy net margin expansion led by the ethanol subsidiary (Modi Biotech) despite stagnant consolidated top-line growth in the bulk edible oil space.
Consolidated Revenue (Q1): ₹155.61 crConsolidated PAT (Q1): ₹12.50 crYoY PAT Growth: 19.14%Consolidated EPS (Q1): ₹9.44Standalone Revenue (Q1): ₹80.80 cr
📅 Short termStable to mildly positive reaction expected due to solid net profit growth and resilient operational margins.
📈 Long termLong-term valuation is tied to the expansion of ethanol capacity (targeting 310 KLPD) and expanding branded FMCG distribution.
⚠ Risk flags
- Consolidated top-line growth remains stagnant YoY
- Commodity price volatility impacting Bulk edible oil margins
- Dependency on government offtake policies for ethanol segment
Key Highlights
Consolidated revenue from operations stood at ₹155.61 Cr vs ₹155.03 Cr in Q1 FY26 (+0.37% YoY)
Consolidated PAT increased 19.14% YoY to ₹12.50 Cr from ₹10.49 Cr
Consolidated basic and diluted EPS improved to ₹9.44 from ₹7.87 YoY
Standalone revenue grew 6.81% YoY to ₹80.80 Cr with Standalone PAT of ₹2.88 Cr
👀 What to Watch
Monitor capacity utilization at subsidiary Modi Biotech's ethanol operations and volume growth across the branded consumer oil portfolio in upcoming quarters.
Modi Naturals Q4 FY26 PAT Surges 141% to ₹19.7 Cr; Ethanol Capacity Doubled to 282 KLPD
Modi Naturals reported a strong Q4 FY26 with revenue growing 28% to ₹243 crore and PAT jumping 141% to ₹19.7 crore. The company successfully commissioned Phase 2 of its ethanol expansion, more than doubling capacity to 282 KLPD, which is expected to drive significant growth in FY27. Operational efficiency improved with ROCE rising to 19.9% and working capital days reducing to 62. The consumer division also hit a record quarterly revenue of ₹50.9 crore, supported by growth in the pasta and packaged foods categories.
Key Highlights
Q4 FY26 PAT increased by 141% YoY to ₹19.7 crore, while EBITDA grew 51.8% to ₹24.5 crore.
Ethanol capacity expanded from 130 KLPD to 282 KLPD, with a current order book of ₹400 crore for 47.9k KL.
Full-year FY26 ROCE improved to 19.9% from 18.3%, reflecting better capital productivity and earnings quality.
Consumer division achieved its highest-ever quarterly revenue of ₹50.9 crore in Q4 FY26.
Cash flow from operations strengthened to ₹61.1 crore for FY26 compared to ₹48.8 crore in FY25.
👀 What to Watch
Investors should monitor the utilization levels of the newly expanded ethanol capacity in FY27, as this will be the primary driver for margin expansion. The company's shift toward a branded consumer portfolio and improved working capital management makes it a strong watch in the FMCG and Bio-energy space.
Modi Naturals FY26 PAT Jumps 62% to ₹50.3 Cr; Targets Up to ₹965 Cr Revenue for FY27
Modi Naturals delivered a robust FY26 performance with consolidated revenue growing 8.5% YoY to ₹719.2 crore and PAT surging 62.1% to ₹50.3 crore. The growth was primarily driven by the Ethanol division, where capacity expanded 117% over two years to 282 KLPD, and improved operational efficiencies. The company strengthened its balance sheet by reducing its Debt/Equity ratio from 1.22 to 0.94 and improving ROCE to 19.9%. Management has issued aggressive guidance for FY27, targeting revenue between ₹925-965 crore and EBITDA of ₹100-105 crore.
Key Highlights
FY26 Revenue grew 8.5% to ₹719.2 cr, while EBITDA increased 31.2% to ₹73.5 cr with a margin of 10.2%.
PAT rose 62.1% to ₹50.3 cr, which includes a ₹4.9 cr insurance claim for business interruption.
Ethanol capacity reached 282 KLPD following Phase II commencement, with a ₹400 cr order book from OMCs.
Net Working Capital days improved to 62 days from 66 days, and Debt/Equity reduced to 0.94.
FY27 guidance projects significant growth with Revenue targets of ₹925-965 cr and PAT of ₹66-70 cr.
👀 What to Watch
The company is at an inflection point with its Ethanol division becoming a major growth engine alongside a steady consumer business. Investors should watch for the successful ramp-up of Phase II ethanol utilization and the achievement of the ambitious FY27 revenue guidance.
Modi Naturals Appoints B. Chhawchharia & Co as New Statutory Auditors
Modi Naturals Limited has announced the resignation of its statutory auditor, M/s Doogar & Associates, effective May 13, 2026. The Board has concurrently approved the appointment of M/s B. CHHAWCHARIA & CO. to fill the casual vacancy, subject to shareholder approval. This transition aims to align audit processes across the group, as the new firm already audits the company's material subsidiary, Modi Biotech Private Limited. The move is intended to enhance operational synergies and consistency in financial reporting.
Key Highlights
Resignation of M/s Doogar & Associates effective May 13, 2026
Appointment of M/s B. CHHAWCHARIA & CO. (FRN: 305123E) to fill the casual vacancy
New auditor already serves the material subsidiary, Modi Biotech Private Limited
Strategic move to ensure consistency in audit processes and operational synergies across the Group
👀 What to Watch
Investors should note the change as a routine governance update aimed at group-level efficiency; monitor the upcoming General Meeting for formal shareholder approval.
Modi Naturals Appoints New Statutory Auditors to Align Group Audit Processes
Modi Naturals Limited has accepted the resignation of M/s Doogar & Associates as Statutory Auditors effective May 13, 2026. To fill the casual vacancy, the Board has appointed M/s B. CHHAWCHARIA & CO., a firm established in 1966 with extensive experience. The new auditor already handles the company's material subsidiary, Modi Biotech Private Limited, which is expected to improve group-wide audit consistency and operational synergies. This appointment is subject to the approval of shareholders at the next General Meeting.
Key Highlights
Resignation of M/s Doogar & Associates (FRN: 000561N) effective May 13, 2026.
Appointment of M/s B. CHHAWCHARIA & CO. (FRN: 305123E) to fill the casual vacancy.
Strategic alignment as the new auditor already serves material subsidiary Modi Biotech Private Limited.
M/s B. CHHAWCHARIA & CO. brings experience dating back to its establishment in 1966.
👀 What to Watch
No immediate action is required as the change appears to be a strategic move for group-level audit synergy. Investors should confirm the appointment is ratified in the upcoming shareholder meeting.
Modi Naturals FY26 Net Profit Jumps 94% to ₹60.28 Cr; Revenue Up 8.5%
Modi Naturals reported a robust performance for the financial year ended March 31, 2026, with consolidated net profit nearly doubling to ₹60.28 crore from ₹31.03 crore in the previous year. Annual revenue from operations grew by 8.5% YoY to reach ₹719.18 crore. The fourth quarter was exceptionally strong, with net profit surging 141% YoY to ₹19.67 crore. Additionally, the company announced a change in statutory auditors and the shifting of its registered office to its corporate premises.
Key Highlights
Consolidated Net Profit for FY26 rose 94.3% YoY to ₹60.28 crore.
Annual Revenue from Operations increased to ₹719.18 crore compared to ₹662.91 crore in FY25.
Q4 FY26 Net Profit saw a massive jump of 141% YoY, reaching ₹19.67 crore.
Basic Earnings Per Share (EPS) improved significantly to ₹38.01 from ₹23.25 in the previous year.
Appointment of M/s B. CHHAWCHARIA & CO. as new Statutory Auditors following the resignation of M/s Doogar & Associates.
👀 What to Watch
The significant expansion in profit margins and strong Q4 performance are very positive; however, investors should monitor the auditor transition to ensure continued reporting transparency.
Modi Naturals FY26 Net Profit Rises 30% to ₹40.28 Cr; Revenue Grows 8.5% YoY
Modi Naturals Limited reported a strong financial performance for FY26, with consolidated net profit climbing to ₹40.28 crore from ₹31.03 crore in FY25. Revenue from operations saw a steady increase of 8.5%, reaching ₹719.18 crore for the full year. The company also announced the resignation of its statutory auditor, M/s Doogar & Associates, and the subsequent appointment of M/s B. Chhawcharia & Co. Additionally, the board approved shifting the registered office to Okhla Industrial Area for better operational alignment.
Key Highlights
FY26 Consolidated Net Profit grew 29.8% YoY to ₹40.28 crore
Annual Revenue from Operations increased to ₹719.18 crore vs ₹662.91 crore in FY25
Q4 FY26 Revenue surged to ₹243.08 crore, up from ₹189.90 crore in the same quarter last year
Earnings Per Share (EPS) for the full year rose to ₹30.01 from ₹23.25
Statutory Auditor change and Registered Office relocation approved by the Board
👀 What to Watch
The strong earnings growth and improved EPS signal healthy business momentum. Investors should maintain a positive outlook while keeping an eye on the seamless transition of the auditing process.
Modi Naturals Credit Rating Upgraded to IVR BBB/Stable for Rs 65 Crore Bank Facilities
Infomerics Valuation and Ratings has upgraded the credit ratings for Modi Naturals Limited's bank facilities totaling Rs. 65.00 crore. The long-term rating has been revised upward to IVR BBB with a Stable outlook, while the short-term rating has been upgraded to IVR A3+. This upgrade is based on the company's improved operational and financial performance during FY25 and the first nine months of FY26. The rated facilities include a Rs. 55 crore Cash Credit and a Rs. 10 crore Letter of Credit/Bank Guarantee.
Key Highlights
Long-term rating upgraded to IVR BBB/Stable for Rs. 55.00 crore Cash Credit facility
Short-term rating upgraded to IVR A3+ for Rs. 10.00 crore non-fund based facilities
Total bank loan facilities reviewed and rated amount to Rs. 65.00 crore
Rating revision reflects positive financial performance evaluation for FY25 and 9MFY26
👀 What to Watch
Investors should view this credit upgrade as a positive indicator of the company's improving financial health and reduced credit risk. This could potentially lead to lower borrowing costs and better access to capital in the future.
Modi Naturals to Close Pilibhit Unit and Sell Machinery for ₹63 Lakhs
Modi Naturals Limited has announced the closure of its manufacturing unit in Pilibhit, Uttar Pradesh, citing operational non-viability. The unit contributed approximately ₹16 crores (4%) to the company's standalone turnover and ₹90 lakhs (0.81%) to its net worth in the last financial year. The company is selling the plant and machinery for ₹63 lakhs while retaining the land and building assets. Management expects no material adverse impact as production will be absorbed by another nearby facility with spare capacity.
Key Highlights
Closure of Pilibhit manufacturing unit due to non-viability of operations
Unit contributed ₹16 crores (4% of standalone turnover) and ₹90 lakhs (0.81% of net worth)
Plant and machinery sold for ₹63 lakhs to a non-promoter buyer; land and building retained
Production volumes to be absorbed by a nearby solvent extraction plant with adequate spare capacity
Transaction expected to be completed by April 23, 2026
👀 What to Watch
This is a strategic consolidation move to eliminate a non-viable unit with minimal impact on overall revenue. Investors should monitor if the consolidation leads to improved margins in the bulk oil segment.
Modi Naturals Doubles Ethanol Capacity to 282 KLPD at Chhattisgarh Plant
Modi Naturals' wholly-owned subsidiary, Modi Biotech Private Limited, has commenced commercial operations at its expanded grain-based ethanol plant in Chhattisgarh. The facility's capacity has been significantly increased from 130 KLPD to 282 KLPD, representing a 117% expansion in production capability. This strategic move aligns with the Government of India's Ethanol Blended Petrol (EBP) Programme, positioning the company to benefit from rising biofuel demand. The expansion is expected to enhance operational efficiencies and contribute meaningfully to the company's revenue growth in the coming quarters.
Key Highlights
Ethanol production capacity enhanced from 130 KLPD to 282 KLPD
Commencement of commercial operations at the expanded facility of subsidiary Modi Biotech Private Limited
Strategic alignment with the Government of India's Ethanol Blended Petrol (EBP) Programme
Expected to drive higher production volumes and improve overall operational efficiencies
👀 What to Watch
Investors should view this as a major growth milestone that significantly scales the company's high-margin ethanol business. Monitor the upcoming quarterly results for the impact of this capacity ramp-up on the company's profitability and revenue mix.
Modi Naturals Q3 PAT Jumps 28.5% YoY; FY26 Revenue Guidance Revised Downward
Modi Naturals reported a strong 28.5% YoY growth in Q3FY26 PAT to ₹10.0 crore, despite a 2.8% dip in consolidated revenue to ₹174.1 crore. For the 9MFY26 period, PAT rose 33.9% to ₹30.6 crore, driven by improved operating leverage and lower finance costs from debt repayment. However, the company has lowered its FY26 revenue guidance to ₹720-730 crore from ₹850-880 crore due to delays in commissioning its 180 KLPD ethanol expansion. The ethanol division remains the primary growth catalyst, with total capacity set to reach 310 KLPD by the end of February 2026.
Key Highlights
Q3FY26 PAT increased by 28.5% YoY to ₹10.0 crore, while EBITDA grew 20.7% to ₹16.0 crore.
9MFY26 EBITDA margins expanded to 10.3% from 8.4% YoY, aided by softer raw material costs and lower finance charges.
Ethanol capacity expansion of 180 KLPD is scheduled for commissioning by late February 2026, taking total capacity to 310 KLPD.
FY26 revenue guidance slashed to ₹720-730 crore (previously ₹850-880 crore) due to ethanol project delays.
Consumer division revenue stood at ₹46.3 crore in Q3, showing resilience despite GST-related billing disruptions in October 2025.
👀 What to Watch
Investors should monitor the successful commissioning and ramp-up of the 180 KLPD ethanol facility in Q4, as this is critical for meeting revised targets. While the guidance cut is a short-term negative, the improving margin profile and debt reduction are positive indicators for long-term stability.
Modi Naturals Q3 Net Profit Rises 28% YoY to ₹10.04 Cr Despite Marginal Revenue Dip
Modi Naturals reported a consolidated net profit of ₹10.04 crore for the quarter ended December 31, 2025, representing a 28.5% growth compared to ₹7.82 crore in the previous year. While revenue from operations saw a slight decline of 2.7% YoY to ₹174.09 crore, the company significantly improved its bottom line through reduced finance costs and strong subsidiary performance. For the nine-month period, PAT surged by 33.9% to ₹30.61 crore. The subsidiary, Modi Biotech Private Limited, played a crucial role, contributing ₹81.19 crore to the quarterly revenue and ₹8.92 crore to the profit.
Key Highlights
Consolidated Net Profit increased to ₹10.04 crore in Q3 FY26 from ₹7.82 crore in Q3 FY25.
Revenue from operations stood at ₹174.09 crore, down slightly from ₹179.02 crore YoY.
Finance costs decreased significantly to ₹1.82 crore from ₹3.14 crore in the year-ago quarter.
Subsidiary Modi Biotech Private Limited contributed ₹81.19 crore in revenue and ₹8.92 crore in PAT for the quarter.
Nine-month PAT grew to ₹30.61 crore compared to ₹22.86 crore in the corresponding period last year.
👀 What to Watch
Investors should note the strong profitability growth driven by the biotech subsidiary and efficient cost management. The reduction in finance costs suggests improving financial health, making it a stock to watch for further margin expansion.
Modi Naturals Q3 FY26 Consolidated PAT Rises 28.5% YoY to ₹10.04 Cr; Revenue at ₹174.09 Cr
Modi Naturals reported a strong bottom-line performance for the quarter ended December 31, 2025, with consolidated Net Profit rising to ₹10.04 crore from ₹7.82 crore in the same period last year. While revenue from operations saw a marginal decline to ₹174.09 crore compared to ₹179.02 crore YoY, the company's profitability improved significantly. The nine-month performance also showed robust growth, with PAT reaching ₹30.61 crore against ₹22.86 crore in the previous year. The subsidiary, Modi Biotech, played a crucial role, contributing nearly 47% of the group's quarterly revenue.
Key Highlights
Consolidated Net Profit for Q3 FY26 increased by 28.5% YoY to ₹1,004.43 lakhs.
Revenue from operations for the quarter stood at ₹17,409.31 lakhs, slightly down from ₹17,901.68 lakhs in Q3 FY25.
Nine-month (9M FY26) PAT grew by 33.9% to ₹3,061.00 lakhs compared to ₹2,286.49 lakhs in 9M FY25.
Subsidiary Modi Biotech Private Limited contributed ₹8,118.71 lakhs in revenue and ₹892.05 lakhs in PAT during the quarter.
Earnings Per Share (EPS) for the quarter improved to ₹7.55 from ₹5.88 in the corresponding previous year quarter.
👀 What to Watch
Investors should focus on the company's improving margins and the strong contribution from its biotech subsidiary which is driving profitability. The stock may see positive momentum due to the significant jump in net profit despite stagnant revenue growth.
